Healthy
Conditions
Brief summary
The aim of the study is to evaluate the effect of nilotinib on the pharmacokinetics and pharmacodynamics of metformin in healthy male adults
Detailed description
Pharmacokinetics and pharmacodynamics of metformin without coadministration of nilotinib will be compared with those after administration of nilotinib.
Interventions
DRUGMetformin
Single administration of metformin
DRUGMetformin + Nilotinib
Coadministration of metformin and nilotinib
Sponsors
Hyewon Chung
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
19 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy male subjects between the ages of 19 and 50 years * Subjects with body mass index (BMI) between 18.5 and 29.9 kg/m2 and weight more than 50 kg * Subjects who agree with performing contraception during the study * Subjects who provides written informed consent
Exclusion criteria
* Subjects who have a current or prior history of cardiovascular, respiratory, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, skin, psychiatric, or neurological diseases that is clinically significant * Subjects who have clinically significant allergic history or allergy to metformin, nilotinib, or other components of drug * Subjects with history of galactose intolerance, lapp lactase deficiency, or glucose-galactose malabsorption * Subjects with hypokalemia or hypomagnesemia at screening * Subjects with QTcF \> 450 or clinically significant findings on 12-lead ECG at screening * Subjects with fasting plasma glucose lower than 70 mg/dL or upper than 126 mg/dL at screening * Subjects who have history of gastrointestinal surgery * Subjects with creatinine clearance ≤ 60mL/min at screening * Subjects with AST or ALT ≥ 2-folds of upper normal limit * Subjects who reports less than 12 points on taste test at screening * Subjects who have administrated drugs that are known to cause significant drug-drug interaction with investigational drugs within 2 weeks prior to dosing * Whole blood donation within 60 days prior to dosing, or apheresis donation within 20 days prior to dosing, or received blood donation within 30 days prior to dosing * Subjects who participated in a previous clinical trial within 6 months prior to dosing * Subjects with a history of alcohol abuse * Subjects who are determined as unsuitable for clinical trial participation by investigator's decision
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cmax | 24 hours post-dose | maximum concentration |
| AUCinf | 24 hours post-dose | Area under the concentration-time curve from time of administration extrapolated to infinity |
| Gmax | 3 hours from 2 hour post-dose | maximum glucose level during oral glucose tolerance test |
| AUGC | 3 hours from 2 hour post-dose | Area under the concentration-time curve during oral glucose tolerance test |
Secondary
| Measure | Time frame |
|---|---|
| Taste test | 7 hour post-dose |
Countries
South Korea
Outcome results
None listed